<p>Aldeyra 治療公司（NASDAQ:ALDX）在八月份的空頭頭寸顯著增加。截至 8 月 15 日，空頭頭寸總計 2,920,000 股，比 7 月 31 日的 2,560,000 股增加了 14.1%。公司約 5.1% 的股票被做空。根據平均交易量 453,900 股，目前的償付日比率為 6.4 天。</p>
<p>獲取 <strong>Aldeyra 治療</strong> 警報：</p>
<h2>Aldeyra 治療股票上漲 7.1%</h2>
<p>ALDX 股票週五開盤價為$5.76。Aldeyra 治療公司的 12 個月最低價為$1.42，最高價為$7.79。該公司的市值為 3.4193 億美元，市盈率為-11.28，β係數為 1.45。公司的 50 天移動平均價為$4.14，200 天移動平均價為$3.88。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些研究分析師最近對該股發表了評論。StockNews.com 在 5 月 22 日星期三的研究報告中將 Aldeyra 治療股票的評級從 “持有” 調降至 “賣出”。Oppenheimer 在 5 月 6 日星期一的研究報告中重申了 “表現優異” 評級，並設定了$10.00 的目標價。最後，HC Wainwright 在 8 月 9 日星期五的報告中重申了 “買入” 評級，並設定了$10.00 的目標價。</p>
<p><strong>查看我們對 Aldeyra 治療的最新研究報告</strong></p>
<h2>對 Aldeyra 治療的對沖基金意見</h2>
<p>一些大型投資者最近調整了他們在該公司的持股。SG Americas Securities LLC 在第二季度收購了 Aldeyra 治療公司的新股，價值約$38,000。Diversified Trust Co 在第二季度購入了 Aldeyra 治療公司的新股，價值約$41,000。NorthRock Partners LLC 在第四季度收購了 Aldeyra 治療公司的新股，價值$42,000。Kingswood Wealth Advisors LLC 在第一季度購入了 Aldeyra 治療公司的新股，價值$49,000。最後，Laidlaw Wealth Management LLC 在第二季度將其在 Aldeyra 治療公司的持股增加了 32.6%。Laidlaw Wealth Management LLC 現在擁有 16,875 股這家生物技術公司的股票，價值$56,000，在上個季度購入了額外的 4,150 股。機構投資者和對沖基金擁有該公司 59.71% 的股份。</p>
<h2>Aldeyra 治療公司簡介（獲取免費報告）</h2>
<p>Aldeyra 治療公司是一家專注於開發新型治療方案，有望改善免疫介導疾病患者生活質量的臨牀階段生物技術公司。該公司的兩個主要化合物，reproxalap 和 ADX-629，針對反應性醛類物質（RASP），這些物質在眼部和全身炎症性疾病中升高，導致通過激活一系列炎症因子，包括 NF-κB、炎症小體和清道夫受體 A，引起細胞因子釋放水平升高。</p>
<h2>特色文章</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Aldeyra 治療</li>
<li>解析醫療保健股票：為什麼您可能想要投資</li>
<li>伯肯斯托克的突然下滑——為什麼它可能是您下一個大贏家</li>
<li>如何投資生物技術股</li>
<li>為什麼戴爾可以在人工智能和其他領域繼續取得成功</li>
<li>每股收益計算器：如何計算 EPS</li>
<li>維娃的股價因 Q2 業績大漲而飆升——不要錯過</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ ⭕ [緊急] 剛剛觸發購買警報（來自市場幕後）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2"/></p>
<h2>您現在是否應該投資$1,000 在 Aldeyra 治療公司？</h2>
<p>在考慮 Aldeyra 治療公司之前，您可能希望聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了華爾街頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的五隻股票...而 Aldeyra 治療公司不在名單上。</p>
<p>儘管 Aldeyra 治療公司目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Aldeyra治療

<p>Aldeyra 治療（NASDAQ:ALDX）的空頭頭寸增加了 14.1%，截至 8 月 15 日達到 2,920,000 股，高於 7 月 31 日的 2,560,000 股。目前，公司有 5.1% 的股份被空頭持有，股票的償付天數比率為 6.4 天。該股市值為 9300 萬美元，目前股價為 0.76 美元，12 個月內最高價為 0.79 美元。分析師對該股的評級各不相同，一些分析師下調了他們的預測，而另一些則維持 “買入” 建議。機構投資者持有該公司的股份比例為 59.71%</p>

<p>Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the recipient of a significant increase in short interest in August. As of August 15th, there was short interest totalling 2,920,000 shares, an increase of 14.1% from the July 31st total of 2,560,000 shares. Approximately 5.1% of the company's stock are sold short. Based on an average trading volume of 453,900 shares, the days-to-cover ratio is currently 6.4 days.</p>
<div class="lb-trans"><p>Aldeyra 治療公司（NASDAQ:ALDX）在八月份的空頭頭寸顯著增加。截至 8 月 15 日，空頭頭寸總計 2,920,000 股，比 7 月 31 日的 2,560,000 股增加了 14.1%。公司約 5.1% 的股票被做空。根據平均交易量 453,900 股，目前的償付日比率為 6.4 天。</p>
</div><p>Get <strong>Aldeyra Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aldeyra 治療</strong> 警報：</p>
</div><h2>Aldeyra Therapeutics Stock Up 7.1 %</h2>
<div class="lb-trans"><h2>Aldeyra 治療股票上漲 7.1%</h2>
</div><p>Shares of ALDX stock opened at $5.76 on Friday. Aldeyra Therapeutics has a 12 month low of $1.42 and a 12 month high of $7.79. The company has a market cap of $341.93 million, a PE ratio of -11.28 and a beta of 1.45. The business's 50 day moving average is $4.14 and its two-hundred day moving average is $3.88.</p>
<div class="lb-trans"><p>ALDX 股票週五開盤價為$5.76。Aldeyra 治療公司的 12 個月最低價為$1.42，最高價為$7.79。該公司的市值為 3.4193 億美元，市盈率為-11.28，β係數為 1.45。公司的 50 天移動平均價為$4.14，200 天移動平均價為$3.88。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research analysts have recently commented on the stock. StockNews.com lowered shares of Aldeyra Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Wednesday, May 22nd. Oppenheimer reissued an &#34;outperform&#34; rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, May 6th. Finally, HC Wainwright restated a &#34;buy&#34; rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a report on Friday, August 9th.</p>
<div class="lb-trans"><p>一些研究分析師最近對該股發表了評論。StockNews.com 在 5 月 22 日星期三的研究報告中將 Aldeyra 治療股票的評級從 “持有” 調降至 “賣出”。Oppenheimer 在 5 月 6 日星期一的研究報告中重申了 “表現優異” 評級，並設定了$10.00 的目標價。最後，HC Wainwright 在 8 月 9 日星期五的報告中重申了 “買入” 評級，並設定了$10.00 的目標價。</p>
</div><p><strong>Check Out Our Latest Research Report on Aldeyra Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Aldeyra 治療的最新研究報告</strong></p>
</div><h2>Hedge Funds Weigh In On Aldeyra Therapeutics</h2>
<div class="lb-trans"><h2>對 Aldeyra 治療的對沖基金意見</h2>
</div><p>Several large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Aldeyra Therapeutics in the 2nd quarter valued at approximately $38,000. Diversified Trust Co bought a new stake in shares of Aldeyra Therapeutics in the second quarter valued at approximately $41,000. NorthRock Partners LLC acquired a new stake in shares of Aldeyra Therapeutics in the fourth quarter worth $42,000. Kingswood Wealth Advisors LLC bought a new position in Aldeyra Therapeutics during the first quarter worth $49,000. Finally, Laidlaw Wealth Management LLC raised its stake in Aldeyra Therapeutics by 32.6% during the 2nd quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 4,150 shares during the last quarter. Institutional investors and hedge funds own 59.71% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了他們在該公司的持股。SG Americas Securities LLC 在第二季度收購了 Aldeyra 治療公司的新股，價值約$38,000。Diversified Trust Co 在第二季度購入了 Aldeyra 治療公司的新股，價值約$41,000。NorthRock Partners LLC 在第四季度收購了 Aldeyra 治療公司的新股，價值$42,000。Kingswood Wealth Advisors LLC 在第一季度購入了 Aldeyra 治療公司的新股，價值$49,000。最後，Laidlaw Wealth Management LLC 在第二季度將其在 Aldeyra 治療公司的持股增加了 32.6%。Laidlaw Wealth Management LLC 現在擁有 16,875 股這家生物技術公司的股票，價值$56,000，在上個季度購入了額外的 4,150 股。機構投資者和對沖基金擁有該公司 59.71% 的股份。</p>
</div><h2>Aldeyra Therapeutics Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Aldeyra 治療公司簡介（獲取免費報告）</h2>
</div><p>Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.</p>
<div class="lb-trans"><p>Aldeyra 治療公司是一家專注於開發新型治療方案，有望改善免疫介導疾病患者生活質量的臨牀階段生物技術公司。該公司的兩個主要化合物，reproxalap 和 ADX-629，針對反應性醛類物質（RASP），這些物質在眼部和全身炎症性疾病中升高，導致通過激活一系列炎症因子，包括 NF-κB、炎症小體和清道夫受體 A，引起細胞因子釋放水平升高。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Aldeyra Therapeutics</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win</li>
<li>How to Invest in Biotech Stocks</li>
<li>Why Dell Can Continue Winning in AI and Beyond</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out</li>
</ul>
<div class="lb-trans"><h2>特色文章</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Aldeyra 治療</li>
<li>解析醫療保健股票：為什麼您可能想要投資</li>
<li>伯肯斯托克的突然下滑——為什麼它可能是您下一個大贏家</li>
<li>如何投資生物技術股</li>
<li>為什麼戴爾可以在人工智能和其他領域繼續取得成功</li>
<li>每股收益計算器：如何計算 EPS</li>
<li>維娃的股價因 Q2 業績大漲而飆升——不要錯過</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ ⭕ [URGENT] Buy Alert just triggered (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ ⭕ [緊急] 剛剛觸發購買警報（來自市場幕後）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9186&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Aldeyra Therapeutics right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 在 Aldeyra 治療公司？</h2>
</div><p>Before you consider Aldeyra Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Aldeyra 治療公司之前，您可能希望聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了華爾街頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的五隻股票...而 Aldeyra 治療公司不在名單上。</p>
</div><p>While Aldeyra Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Aldeyra 治療公司目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Aldeyra 治療公司（納斯達克代碼：ALDX）空頭頭寸大幅增加